Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 November 2019 | Story Leonie Bolleurs | Photo Supplied
Bennie
Bennie Botha brings another element of teaching to the classroom for future healthcare professionals. Here, he facilitates a session with students from the School of Nursing.

These days we are surrounded by technology. Interactive whiteboards, 3-D printers, smartphones, laptops, e-books, and virtual reality (VR).

VR was previously associated with the gaming industry, but today it has many uses, including the healthcare industry and more specifically, the field of nursing. 

A staff member in the School of Nursing at the University of the Free State (UFS), Bennie Botha, explains that he always had a fascination with VR. With VR being more affordable to the general user and with him working in the School of Nursing, he wanted to make a difference by providing a more financially sustainable way for students to integrate theory and practical work. 

It was then that Botha, in collaboration with staff from the Department of Computer Science and Informatics and the School of Nursing, developed a virtual environment to train Nursing students as part of his master’s thesis. The title of his dissertation is: Measuring the usability and user experience of virtual reality as a teaching and learning method for nursing students. His supervisor, Dr Lizette de Wet of the Department of Computer Science and Informatics, said the cooperation between two disciplines is important. “This research can make a big contribution towards teaching and learning,” she said. 
 
Adding to existing technology-rich environment

This simulation in a computer-generated environment adds another element to teaching. Instead of only listening to a lecturer, students are immersed in a relevant teaching scenario and are able to interact within a 3D medical institution, treating and taking care of 3D patients. 

The UFS School of Nursing has implemented this first for South Africa, using VR as an instrument to train nursing students. Currently, third-year students and postgraduate Paediatrics students are exposed to this way of training.

This new invention for the School of Nursing adds to the already existing technology-rich environment of the Clinical Simulation Unit within the school; a facility where healthcare students are exposed to training in a safe environment without harming the patient, using high-fidelity patient manikins.

Cost-effective simulation platform

According to Botha, VR provides a cost-effective simulation platform that can be used to augment high-fidelity simulations. “It is also a low-cost alternative for institutions that do not have the capital to implement high-fidelity simulations. By implementing new innovative teaching methods, we aim to provide quality healthcare professionals who can showcase the educational excellence of the School of Nursing at the UFS,” says Botha. 

Rector content

Rector and Vice-Chancellor, Prof Francis Petersen, visited the School of Nursing and engaged in the simulator-based game.
(Photo: Supplied)


He explains the process: “Virtual reality provides students with an opportunity to learn by engaging in a simulator-based game. The virtual environment requires the students to perform a respiratory foreign-body object simulation scenario. Before each virtual simulation session, students are briefed and given the relevant outcomes of the scenario. Students also receive a quick tutorial on the use of the controllers and the head-mounted display.”

“Once a session is complete, a debriefing session is held where students can reflect on the outcome of the simulation. They can view a recording of their own actions for self-reflection afterwards.”

Botha believes the VR environment he created for Nursing students contributes to the Fourth Industrial Revolution, giving the UFS a competitive edge in new developments and the use of innovative teaching and learning technology. 




News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept